Biogen Inc.
—- Market cap
- $31.81B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $31.81B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: BIIB stock price at discount vs TMO $215.43 current versus $298.87 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TMO's multiple
Implied fair value · at BIIB's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOGEN INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
THERMO FISHER SCIENTIFIC INC. · implied price per share
Bear
$232.95
Base
$271.64
Bull
$310.46
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BIIB's lower multiples deserve re-rating without requiring TMO-like growth, then BIIB is worth considering, because it is cheaper than TMO on P/E, P/S, EV/EBITDA, and EV/Revenue while still showing solid operating margin and ROIC.
BIIB trades at 23.1x P/E versus TMO at 32.4x, with a model-implied price of $284.56 versus a current price of $202.95, suggesting 40.2% upside on TMO-multiple framework. However, that uplift is tempered by BIIB's valuation already sitting near the upper end of its historical band and by a DCF range that is materially below the current price.
Supporting Metrics